QR kód

Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study)

Abstract Background This study evaluated the efficacy and safety of generic semaglutide compared with innovator Semaglutide in Indian adults with type 2 diabetes mellitus (T2DM). Methods This Phase 3, multicenter, randomized, active-controlled, non-inferiority trial enrolled 320 adults with T2DM ina...

Celý popis

Uloženo v:
Hlavní autoři: Nitin Kapoor, Shehla Shaikh, Saptarshi Bhattacharya, Sanjay Kalra, Sambit Das, Sunil Kota, Vipul Khandelwal, Arindam Naskar, Amol Dange, Sanket Sorate, Mayura Choudhari, Narayan Deogaonkar, Jayashree Shembalkar, Deepak Varade, Shejole Vivek Samadhan, Shrikant Somani, Richa Giri, Jasminder Singh, Rajesh Kumar Palaparthi, Narendra Prasad, Paramesh Shamanna, Santosh Saklecha, Kushal Bangar, Aruna Mangipudi, Mayur Mayabhate, Nitin Kapure, Akhilesh Sharma, Radhakrishna Vaddem, Mukesh Jaiswal
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2026-04-01
Edice:Cardiovascular Diabetology. Endocrinology Reports
Témata:
Semaglutide
Type 2 diabetes mellitus
GLP-1 receptor agonist
Non-inferiority
Indian population
HbA1c reduction
On-line přístup:https://doi.org/10.1186/s40842-026-00290-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky